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Abstract
Background and Aims: Biosimilar infliximab CT-P13 is approved for all indications of the originator 
product in Europe. Prospective data on its efficacy, safety, and immunogenicity in inflammatory 
bowel diseases are lacking.
Methods: A prospective, nationwide, multicentre, observational cohort was designed to examine 
the efficacy, safety, and immunogenicity of CT-P13 infliximab biosimilar in the induction treatment of 
Crohn’s disease [CD] and ulcerative colitis [UC]. Demographic data were collected and a harmonised 
monitoring strategy was applied. Early clinical remission, response, and early biochemical 
response were evaluated at Week 14, steroid-free clinical remission was evaluated at Week 30. 
Therapeutic drug level was monitored using a conventional enzyme-linked immunosorbent assay.
Results: In all, 210 consecutive inflammatory bowel disease [126 CD and 84 UC] patients were 
included in the present cohort. At Week 14, 81.4% of CD and 77.6% of UC patients showed clinical 
response and 53.6% of CD and 58.6% of UC patients were in clinical remission. Clinical remission 
rates at Week 14 were significantly higher in CD and UC patients who were infliximab naïve, 
compared with those with previous exposure to the originator compound [p < 0.05]. Until Week 30, 
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adverse events were experienced in 17.1% of all patients. Infusion reactions and infectious adverse 
events occurred in 6.6% and 5.7% of all patients, respectively.
Conclusions: This prospective multicentre cohort shows that CT-P13 is safe and effective in the 
induction of clinical remission and response in both CD and UC. Patients with previous infliximab 
exposure exhibited decreased response rates and were more likely to develop allergic reactions.
Keywords:  Biosimilar; CT-P13; Crohn’s disease; efficacy; immunogenicity; inflammatory bowel diseases; infliximab; safety; ulcera-
tive colitis
1. Introduction
Biosimilars are biological medicines that enter the market after the 
patent expiration of the original reference product. The first biosimi-
lar monoclonal antibody, biosimilar infliximab CT-P13 [Remsima®, 
Celltrion, Republic of Korea and Inflectra®, Hospira, UK] received 
marketing authorisation from the European Medicine Agency 
[EMA] in June 2013 for all indications of the originator product.1 
This includes the use of biosimilar infliximab in inflammatory bowel 
diseases [IBD], as an extrapolated indication based on comparative 
clinical studies in ankylosing spondylitis [PLANETAS] and rheuma-
toid arthritis [PLANETRA].2,3
According to a European survey among gastroenterologists in 
2013, there was a lack of confidence in using biosimilar infliximab 
in IBD.4 Concerns have also been raised by several national societies 
with regard to extrapolated indications.5,6 These concerns included 
the dosing of infliximab, which differs between indications, 5 mg/kg 
in IBD and 3 mg/kg in rheumatoid arthritis. The use of concomitant 
immunosuppressive medication is more common in rheumatologi-
cal indications compared with IBD. Accordingly, in the PLANETRA 
study, all patients received combination treatment with methotrexate 
in addition to the originator or biosimilar infliximab.2 Additionally, 
there is difference in the downstream effects of anti-tumour necrosis 
factor-α [anti-TNF] medications in rheumatological conditions and 
in IBD.7,8
In support of extrapolated indications, the European Medicines 
Agency [EMA] requires stringent analytical and pre-clinical compa-
rability exercises as well as comparative clinical studies to demon-
strate biosimilarity.9 Biosimilars may lead to significant cost savings 
and easier access to biologicals with sustained level of care.
As of May 2014, the Hungarian National Health Fund only 
reimburses the biosimilar infliximab [Inflectra®, Hospira, UK] for 
new induction treatment of IBD patients. New induction was defined 
as no infliximab treatment with the originator [or the biosimilar] 
compound in the previous 12 months. Switching from the originator 
compound to the biosimilar infliximab is not allowed according to 
current regulations.
Data on the use of the biosimilar infliximab CT-P13 in IBD are 
limited.10,11 Therefore, we designed a prospective, nationwide, mul-
ticentre, observational study to examine the efficacy, safety, and 
immunogenicity of CT-P13 infliximab biosimilar in induction and 
maintenance of remission in Crohn’s disease [CD] and ulcerative 
colitis [UC].
2. Material and Methods
2.1. Patients
The induction phase of this multicentre, nationwide prospective 
observational study was conducted between May 2014 and May 
2015 at 12 sites in Hungary; the maintenance phase is still ongoing. 
Ethical approval was acquired from the National Ethical Committee 
929772-2/2014/EKU [292/2014]). The study was registered at the 
EMA European Network of Centres for Pharmacoepidemiology and 
Pharmacovigilance [ENCEPP/SDPP/9053]. All patients gave written 
informed consent to participation.
Consecutive IBD patients starting on infliximab biosimilar were 
prospectively enrolled in the study. Eligible patients were older than 
18 years and were previously diagnosed either with CD or with UC 
based on clinical, biochemical, endoscopic, and histological find-
ings. In the BCG [Bacillus Calmette-Guerin]-vaccinated population, 
patients with positive tuberculin skin tests and positive quantiferon 
assay [QuantiFERON®-TB Gold, Cellestis Limited, Carnegie, VIC, 
Australia] were ineligible. Standard chest radiographs were also 
obtained during screening. Eligible Crohn’s patients had moderate 
to severe therapy-refractory or steroid-dependent luminal disease, 
or therapy-refractory simple fistulising disease or complex fistulas. 
Eligible patients with ulcerative colitis had therapy-refractory, ster-
oid-dependent or severe acute steroid-refractory colitis. None of the 
patients received infliximab treatment with the originator compound 
within 12 months before initiation of the biosimilar infliximab.
2.2. Study design
Eligible patients received intravenous infusions of the biosimilar 
infliximab CT-P13 [Inflectra®, Hospira, UK] at a dose of 5 mg/kg 
of body weight at Weeks 0, 2, and 6 and then every eight weeks. 
Patients only continued into the maintenance phase of the study if 
clinical remission or response was achieved at Week 14.
The primary endpoint of the study was early clinical remission 
in CD and UC at Week 14. Secondary endpoints were early clini-
cal and biochemical response, immunogenicity, and safety, evalu-
ated at Week 14, and clinical response, remission, and steroid-free 
remission, evaluated at Week 30. Further secondary endpoints of 
the maintenance phase included sustained clinical remission and 
response, biochemical response, mucosal healing, immunogenicity, 
and safety, evaluated at Week 54.
Clinical remission in CD was defined as a Crohn’s Disease 
Activity Index [CDAI] < 150 points or no fistula drainage as assessed 
by the Fistula Drainage Assessment.12,13 Clinical remission in UC was 
defined as a partial Mayo Score [pMayo] of less than 3 points.14 
Clinical response in CD was defined as a decrease in CDAI with 
more than 70 points or at least 50% reduction in the number of 
draining fistulas. Clinical response in UC was defined as a decrease in 
the pMayo score with more than 3 points. At Week 14, response and 
remission were evaluated and defined whether patients were eligible 
for maintenance treatment. Biochemical activity was evaluated by 
measuring total blood count [TBC], serum C-reactive protein [CRP, 
normal cut-off: 5 mg/l], and albumin. The Simple Endoscopic Score 
for Crohn’s Disease [SES-CD] was used to assess mucosal healing in 
CD and the Mayo score was evaluated in UC.15
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The conventional and bridging enzyme-linked immunosorbent 
assay [ELISA] methods were used to measure infliximab biosimilar 
trough level [TL] and anti-drug antibody [ADA] [LISA TRACKER, 
Theradiag, France]. The ELISA kit was validated for accuracy and 
reproducibility of therapeutic drug level monitoring [TDM] of 
the biosimilar infliximab [Theradiag, France/Hospira, UK]. ELISA 
measurements were centralised and performed at the Department of 
Laboratory Medicine, Semmelweis University, Budapest.
2.3. Follow-up, safety, efficacy, and immunogenicity 
evaluations
A nationwide harmonised monitoring strategy was applied, as man-
dated by the National Health Fund. Demographical data collection, 
registration of previous and concomitant medication, monitor-
ing clinical, biochemical and endoscopic responses, perianal imag-
ing, and TDM were performed [Supplementary Table  1, available 
as Supplementary data at ECCO-JCC online]. Laboratory tests at 
additional time points were driven by individual patient needs and 
were left to the discretion of the treating physician.
2.4. Statistical analysis
Data were analysed with the use of SPSS 20.0 software. Descriptive 
statistics were used to characterise patients’ demographics, early 
clinical remission and response rates, and adverse events. Clinical 
response, remission rates, and antidrug antibody positivity rates were 
compared between infliximab-exposed and naïve patients by chi2 test 
or Fisher exact test. Biochemical response and infliximab trough lev-
els were evaluated by t-test with separate variance estimates or one-
way analysis of variance [ANOVA], using Scheffe post-hoc analysis, 
as appropriate; p < 0.05 was considered statistically significant.
3. Results
3.1. Patients and follow-up
In all, 210 consecutive eligible [126 CD and 84 UC] patients from 
12 sites were enrolled in the study. By May 2015, 108 CD and 74 
UC patients reached Week 6 and 97 CD and 58 UC patients reached 
the primary endpoint of Week 14. Week 30 secondary endpoint 
was reached by 58 CD and 25 UC patients. Patient follow-up is 
being continued until Week 54. Until Week 30, CT-P13 treatment 
was stopped in 19 patients due to adverse events [n = 17] or loss of 
response [n = 2; LOR] and 1 patient was lost to follow-up after Week 
14 infusion [Figure 1].
The median disease duration in CD patients was 6 years; 42.1% of 
CD patients had ileocolonic disease, 33.3% exhibited perianal mani-
festation, and 26.2% had gone through previous surgery; 26.2% of 
patients had received previous anti-TNF treatment, 22.3% with the 
originator infliximab [Remicade®, Merck & Co.] and 3.9% with adali-
mumab [Humira®, AbbVie]. At baseline, 47.6% and 62.5% of CD 
patients received concomitant steroid and thiopurine therapy, respec-
tively. The median disease duration in UC patients was 4 years; 57.1% 
of UC patients had extensive disease. At inclusion, 64.7% and 57.3% 
of patients were on concomitant steroid and thiopurine therapy, respec-
tively. Detailed patient demographic data are presented in Table 1.
3.2. Early clinical remission and response
At Week 6, 77.8% [n = 84] of CD patients had clinical response to 
treatment with CT-P13 and 49.1% [n = 53] of CD patients were in 
clinical remission. Among UC patients, 77% [n  = 57] and 67.6% 
[n = 50] had clinical response and remission, respectively [Figure 2a]. 
At Week 14, 81.4% of CD patients [n,=,79] had clinical response 
and 53.6% of CD patients [n,=,52] were in clinical remission; 
77.6% [n = 45] of UC patients had clinical response by Week 14 and 
58.6% [n = 34] were in clinical remission [Figure 2b].
Clinical response rates at Week 6 were significantly higher in 
both CD and UC infliximab-naïve patients compared with those 
previously exposed to the originator compound [87.3 vs. 51.7% in 
CD and 81.4 vs. 60% in UC, p < 0.05 and p < 0.05, respectively 
Figure  2c]. Clinical remission rates at Week 14 were significantly 
higher both in CD and UC patients without previous exposure to 
the originator infliximab compared with those previously exposed 
[60.9% vs. 35,7% in CD and 65.1% vs. 33.3% in UC, p < 0.05 and 
p < 0.05, respectively, Figure 2d].
3.3. Clinical response, remission, and steroid-free 
clinical remission at Week 30
At Week 30, 67.2% of Week 14 responder CD patients [n  =  39] 
maintained clinical response to CT-P13 and 53.4% [n = 31] were in 
LOR: loss of response, AE: adverse event. 1 CD patient was lost to follow-up after week 14. 
Week 30
Week 14
Week 6
Week 0
126 CD and 84 UC 
patients were 
enrolled and 
received week 0. 
infusion of CT-P13
108 CD and 74 UC 
patients received 
week 6 infusion of 
CT-P13
97 CD and 58 UC 
patients received 
week 14 infusion of 
CT-P13
58 CD and 25 UC 
patients received 
week 30 infusion of 
CT-P13
2 patients had LOR
1 patient had AE, 
STOP before week 
30 infusion of CT-
P13
4 patients had AE , 
STOP before week 
14 infusion of CT-
P13
12 patients had AE, 
STOP before week 6 
infusion of CT-P13
Figure 1. Patients and follow-up. LOR, loss of response; AE, adverse event; CD, Crohn’s disease; UC, ulcerative colitis. One CD patient was lost to follow-up after 
Week 14.
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clinical remission [Figure 3]. Difference between naïve patients and 
those with previous infliximab exposure did not reach significance 
either in terms of clinical remission or in clinical response [60% vs. 
38.9%, p = 0.13 and 75% vs. 50%, p = 0.06, respectively]. Steroid-
free clinical remission was reached in 50% of CD patients [n = 29] 
by Week 30. Of note, patients in the anti-TNF exposed subgroup 
of patients had higher response and remission rates at Week 30 if 
they received concomitant azathioprine therapy [12.5% vs. 75%, 
p = 0.01 and 12.5% vs. 62.5%, p = 0.04].
At Week 30, 80% of Week 14 responder UC patients [n = 20] main-
tained clinical response to CT-P13 and 68% of the patients [n = 17] were 
in clinical remission [Figure  3]. Clinical response and remission were 
reached in 84.2% and 78.9% of infliximab-naïve patients compared 
with 66.6% and 33.3% of previously exposed patients (not significant, 
[p = 0.35 and p = 0.06, respectively]). Steroid-free clinical remission was 
achieved in 56% of UC patients [n = 14] by Week 30.
3.4. Biochemical response
In CD patients the mean CRP level was 20.9 mg/l at baseline, which 
decreased to 10.6 mg/l at Week 14 [p = 0.02, Figure 4a]. Mean plate-
let count decreased from 370 G/l at baseline to 330 G/l at Week 14 
[p < 0.001]. Change in the mean serum albumin level between base-
line and Week 14 was not significant [42.1 vs. 43 g/l].
In UC patients mean CRP level was 32.4 mg/l at baseline and 
decreased to 7.5 mg/l at Week 14 [p < 0.001, Figure 4b]. Mean plate-
let count decreased from 403 G/l at baseline to 329 G/l at Week 14 
[p = 0.007]. There was no significant change in the mean albumin 
level of the patients between baseline and Week 14 [41.2 vs. 43.3 g/l].
3.5. Therapeutic drug level monitoring
Mean trough levels [TL] of CD patients were 24.8 [n = 31], 18.4 
[n = 31] and 4.8 μg/ml [n = 61, missing TL analysis n = 36] at Weeks 
2, 6, and 14. In UC patients, mean trough levels were 19.3 [n =1 9], 
6.2 [n = 14], and 3.3 μg/ml [n = 42, missing TL analysis n = 16] at 
Weeks 2, 6, and 14, respectively. Difference between TLs of CD and 
UC patients was significant at Week 6 [p < 0.001]. Patients with pre-
vious infliximab exposure had a tendency towards lower early mean 
TLs compared with patients without previous infliximab exposure 
[15.0 vs. 21.5 μg/ml at Week 2, 7.7 vs. 10.2 μg/ml at Week 6, and 4.8 
vs. 3.2 μg/ml at Week 14, not significant].
Anti-drug antibodies [ADA] were detected in 9.1% [9/99 
patients] of all CD patients at baseline and 21.3% [13/61 patients] 
at Week 14. In infliximab-naïve CD patients, ADA positivity was 4% 
[3/75 patients] and 16.7% [8/48 patients] at baseline and at Week 
14, respectively. In CD patients with previous infliximab exposure, 
ADA positivity was 24.2% [6/24] and 38.5% [5/13] at baseline and 
at Week 14, respectively. Patients exposed to previous infliximab 
treatment had significantly higher baseline ADA positivity as com-
pared with naïve patients [p = 0.006]. At Week 14, 38.5% of previ-
ously exposed patients had ADA positivity compared with 16.7% in 
infliximab-naïve patients [not significant].
ADA was detected in 8.8% [6/68 patients] of all UC patients 
at baseline and 23.8% [10/42 patients] at Week 14. In infliximab-
naïve UC patients, ADA positivity was 3.6% [2/55 patients] and 
21.9% [7/32 patients] at baseline and at Week 14, respectively. In 
UC patients with previous infliximab exposure, baseline ADA posi-
tivity was 30.8% [4/13 patients], and at Week 14 ADA positivity 
was 30% [3/10 patients]. Baseline ADA positivity was detected in 
a significantly higher number of patients who had received previ-
ous infliximab treatment as compared with infliximab-naïve patients 
[p = 0.02]. There was no significant difference in ADA positivity at 
Week 14 between patient groups when stratified according to previ-
ous infliximab exposure.
3.6. Adverse events
Up to Week 30, adverse events had occurred in 17.1% of all 
patients. Infusion reactions occurred in 6.7% [n  = 14] of CT-P13 
treated patients. Ten of the 14 patients experiencing infusion reac-
tion of any severity had previously received the originator inflixi-
mab. Infusion reactions occurred in a significantly higher proportion 
of patients with previous infliximab exposure compared with naïve 
patients [27% vs. 2.5%, p < 0.001]. No infusion reactions occurred 
in patients with previous exposure to adalimumab. Possible delayed 
hypersensitivity occurred in one patient. Infectious adverse events 
occurred in 5.7% of all patients; one patient had invasive fungal 
sepsis, which resulted in her death [Table 2].
4. Discussion
Our results show that biosimilar infliximab CT-P13 induces and 
maintains high clinical remission and response rates in both CD and 
UC patients up to week 30. There was a significant difference in 
the early response and remission rates between patients previously 
exposed to the originator compound as compared with the inflix-
imab-naïve patients. This was associated with significantly higher 
baseline ADA positivity in both CD and UC patients previously 
Table 1. Patient demographics.
CD [n = 126] UC [n = 84]
Gender [male/female] 56/70 47/37
Age at disease onset 
(median [IQR]; years)
24 [19–35] 27 [22–37]
Disease duration (me-
dian [IQR]; years)
6 [3–11] 4 [2–12]
Disease activity at 
baseline
CDAI: 324 [310–353] 
n = 93
MAYO: 9 [IQR: 8–11]
[median [IQR]] PDAI: 10 [IQR: 9–11] 
n = 33
pMAYO: 7 [IQR: 5–9]
Location [L1/L2/L3/L4/ 
all L4; %]
16.7/39.7/42.1/1.6/8.8 -
Extent [E1/E2/E3; %] - 7.1/35.7/57.1
Behaviour [B1/B2/ 
B3; %]
57.9/22.2/19.8 -
Perianal [%] 33.3 -
Previous surgery [%] 26.2 -
Medication ever [%]
 5ASA [local] 84.9 91.7 [51.9]
 Steroids 81.7 91.7
 AZA 87.3 77.1
 CsA - 9.5
 Previous anti-TNF 
[IFX/ADA]
26.2 [22.3/3.9] 19.3 [10.7/5.9]
Medication baseline 
[%]
 5ASA [local] 69.0 80.5
 Steroids 47.6 64.4
 AZA 62.5 57.3
IQR, interquartile range; CD, Crohn’s disease; UC, ulcerative colitis; IFX, 
infliximab; 5ASA, 5-aminosalicylates; AZA, azathioprine; CsA, cyclosporine 
A; TNF, tumour necrosis factor; ADA, anti-drug antibody; PDAI, Pouchitis 
Disease Activity Index; CDAI, Crohn’s Disease Activity Index.
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exposed to the originator compound. Clinical improvement during 
induction was coupled with decreased biochemical activity in both 
CD and UC as compared with baseline.
The ACCENT I trial demonstrated that 39% of Week 2-responder 
CD patients exhibited clinical remission at Week 30 when treated with 
infliximab 5 mg/kg compared with 21% in placebo-treated respond-
ers.16 Additionally, real-life clinical data with the originator support 
high response and remission rates during induction in CD patients.17–19 
In comparison, clinical response and remission in CD patients after 
the induction treatment with CT-P13 were 82% and 54%, respec-
tively, and 67.2% of Week 14-responder CT-P13-treated CD patients 
maintained clinical response up to week 30. This is in line with an 
earlier retrospective national initiative, which demonstrated 86% 
response and 46% remission rates in CD from the same background 
population after induction treatment with the originator compound.20
In the ACT 1 and ACT 2 trials, 69% and 64% of UC patients 
who received 5 mg/kg of infliximab had a clinical response at Week 
8 and 49% and 41% of patients maintained response at Week 30, 
respectively.14 In comparison, in our real-life cohort with CT-P13, 
clinical response was 78% at Week 14. Additionally, 80% of Week-
14 UC responders sustained clinical response at Week 30. This is 
comparable to a retrospective, multicentre analysis that showed 
22% primary non-response to the originator compound in UC.21 
Our findings are also in line with the results of a retrospective study 
and a case series regarding the efficacy of CT-P13 in IBD.10,11
In the present cohort, drug-related adverse events were expe-
rienced in 17.1% of patients until Week 30. This is remarkably 
lower than adverse events reported in either the PLANETAS or the 
PLANETRA study.2,3 We did not detect any cases of latent tuber-
culosis during the study period in our BCG-vaccinated population. 
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Figure 2. Early clinical remission and response. a. Clinical remission and response at Week 6 in CD and in UC. b Clinical remission and response at Week 14 in CD 
and in UC. c. Clinical remission and response at Week 6 in IFX-naïve and exposed patients. *p < 0.05, both in CD and in UC, as compared with previous exposure. 
d. Clinical remission and response at Week 14 in IFX-naïve and exposed patients. *p < 0.05, both in CD and in UC, as compared with previous exposure. CD, 
Crohn’s disease; UC, ulcerative colitis; IFX, infliximab.
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Additionally, changes in the clinical laboratory parameters per se 
were not considered a safety endpoint. The rate of infusion-related 
reactions with CT-P13 in IBD was comparable to those reported 
in the rheumatological studies [6.7% vs. 6.6 and 3.9%]. Of note, 
IBD patients in the present cohort were not routinely premedicated 
with antihistamine, were not necessarily on concomitant immuno-
suppressives, and may have been previously exposed to the origi-
nator compound. In our study population. 22% of CD and 11% 
of UC patients had previously received the originator infliximab. 
Re-initiation of infliximab treatment has previously been shown 
to be an effective and safe therapeutic option.22,23 According to 
the results of the present study, a word of caution is needed, since 
the majority of early infusion reactions occurred in patients with a 
previous anti-TNF exposure by the originator molecule and a drug 
holiday beyond 1 year. Therefore a risk-benefit evaluation is recom-
mended before initiating a long drug holiday in patients in remission, 
and further data are warranted.
Pharmacokinetic evaluation of CT-P13 in IBD has not been previ-
ously reported. In our present study, mean TLs were 24.8, 18.4, and 
4.8 μg/ml in CD and 19.3, 36.2, and 3.3 μg/ml in UC at Weeks 2, 6, 
and 14, respectively. In comparison, a post-hoc analysis of the ACCENT 
I trial found that median Week 14 trough levels of patients with and 
without sustained response to infliximab induction with 5 mg/kg, were 
4.0 and 1.9 μg/ml, respectively24 Interestingly, in our cohort patients 
with previous infliximab exposure had a tendency towards lower early 
TLs compared with naïve patients. This was associated with signifi-
cantly higher baseline ADA positivity [4% vs. 24%] and lower early 
response and remission rates in patients previously exposed to the 
originator compound. ADA positivity in the CT-P13-treated infliximab-
naïve and previously exposed CD patients were 24.2% and 38.5% 
at Week 14, respectively. In comparison, ADA positivity was previ-
ously reported to range between 12.5% to 43% and 0.9% to 14% 
in infliximab-naïve patients with scheduled infliximab infusions of the 
originator compound, depending on the administration of concomi-
tant immunosuppression.25 In comparison, in a head-to-head Japanese 
trial in rheumatoid arthritis, CT-P13 or infliximab was administered 
in combination with methotrexate and ADA were detected in 19.6% 
of patients in the CT-P13 group and 15.1% of patients in the inflixi-
mab group at Week 14.26 The development of antibodies has previously 
been associated with increased risk of infusion reactions and reduced 
response to treatment.27 Additionally, when re-initiating the infliximab 
therapy after a drug holiday, when antibodies to infliximab were detect-
able, the hazard ratio for infusion reaction was 7.7.23 This underlines 
our findings that 10 of 14 patients who experienced infusion reac-
tion of any severity had previously received the originator infliximab. 
Furthermore, it has recently been demonstrated that anti-infliximab 
Table 2. Adverse events.
Adverse event Patient no. [%]
Infections
 Upper respiratory tract infection 6 [2.9%]
 Pneumonia 1 [0.5%]
 Tuberculosis 0 [0%]
 Gastroenteritis 2 [1%]
 Vaginitis 1 [0.5%]
 Urinary tract infection 1 [0.5%]
 Viral infections [influenza, herpes, varicella] 0 [0%]
 Invasive fungal infection 1 [0.5%]
Acute infusion reactions
 Anaphylaxis 1 [0.5%]
 Other 13 [6.2%]
Possible delayed hypersensitivity 1 [0.5%]
Arthralgia 9 [4.3%]
Malignancy 0 [0%]
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Figure 3. Clinical response and remission at Week 30.
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Figure  4. Early biochemical response. a.  Mean CRP levels [± SEM] in CD 
during induction treatment. *p  =  0.02, compared with baseline. b.  Mean 
CRP levels [± SEM] in UC during induction treatment. *p < 0.001, compared 
with baseline. CRP, C-reactive protein; SEM, standard error of the mean; CD, 
Crohn’s disease; UC, ulcerative colitis.
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antibodies in IBD patients recognise and cross-react with CT-P13 and 
neutralise each drug’s activity.28 In contrast, anti-adalimumab antibod-
ies do not cross-react with CT-P13.28 Consistently, no infusion reactions 
occurred in patients with previous adalimumab exposure in our cohort. 
Consequently, ADA to infliximab that were detected at baseline in our 
previously exposed patient population could have been responsible for 
the reduced rate of early clinical response. The clinical importance of 
ADAs detected at baseline [five patients, transient in three patients] in 
the infliximab-naïve population needs further investigation.
This study is a nationwide, multicentre, prospective cohort with 
a harmonised monitoring strategy. However, there are limitations 
to acknowledge. During the induction phase, only clinical and bio-
chemical endpoints were evaluated and therefore the study lacks 
an early endoscopic endpoint. Nevertheless, following the national 
monitoring strategy, endoscopic evaluation will be available at Week 
54 both in CD and in UC patients. Our study did not aim to evalu-
ate interchangeability, as switching from the originator compound to 
the biosimilar [or vice versa] was not allowed by the national health 
authorities. However, preliminary retrospective data are showing 
favourable outcome, and a randomised, double-blind, parallel-
group study, the NOR-SWITCH study [ClinicalTrials.gov identifier: 
NCT02148640] is currently being pursued.10,11,29
Despite the EMA’s strict regulations to granting marketing author-
isation to the first biosimilar monoclonal antibody, several concerns 
have been raised regarding its administration in IBD. So far only lim-
ited data from retrospective real-life experience have been available 
on the use of the biosimilar infliximab CT-P13 in IBD.10,11 Therefore, 
this nationwide cohort was designed to satisfy this unmet need and 
prospectively evaluate the efficacy and safety of CT-P13 in IBD.
To conclude, this prospective multicentre cohort shows that 
CT-P13 is effective and safe in the induction of clinical remission 
and response in both CD and UC. Efficacy and safety of CT-P13 
reported herein is comparable to those of observational studies of 
the originator compound. Importantly, induction treatment with 
the biosimilar infliximab was less effective in patients previously 
exposed to the originator compound. Further data are warranted 
to evaluate the efficacy of CT-P13 in maintaining remission in IBD.
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